SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp (UAMY) is trending as its new joint venture with Americas Gold and Silver for a state-of-the-art hydromet plant and a crucial DLA contract highlight its role in securing domestic critical mineral supply. The community is keenly observing its potential amidst government initiatives to reduce foreign dependency, even as discussions about market manipulation and short selling persist.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is experiencing a surge following positive top-line data from its Phase 2a trial for EVO301 in moderate-to-severe atopic dermatitis, leading to active community discussions around its potential and contributing to a broader biotech sector rally.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is caught in a market-wide software sector sell-off, with intense debate among investors over whether AI advancements pose an existential threat to its core business or if the stock is now massively oversold, presenting a generational buying opportunity given its strong fundamentals and significant buyback potential.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is a trending topic following its recent earnings, which included a revenue miss but an EPS beat, sparking a community debate between those who see it as an undervalued fintech player with a promising management turnaround plan and others concerned about its debt, shrinking margins, and the broader industry's vulnerability to AI.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog's strong Q4 earnings beat is sparking investor conversation, contrasting with softer full-year guidance that has some questioning its valuation and competitive landscape. The market is debating whether its AI-driven growth can lead a broader software sector rebound, or if recent sell-offs reflect ongoing headwinds.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as its latest earnings report revealed a wider Q4 loss, yet this is largely overshadowed by strong 2026 profitability guidance and record membership growth. Community sentiment is divided between optimism for market share expansion and skepticism regarding the ambitious future projections in a volatile healthcare sector.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following a strong earnings report that showcased robust revenue and GMV growth, significantly reduced cash burn, and a clear path to profitability by late 2026. The community is buzzing about this financial turnaround and recent analyst upgrades touting Jumia as the "Amazon of Africa" in an accelerating e-commerce market.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending following an impressive earnings beat, robust subscriber growth, and strong guidance, which has prompted multiple analyst upgrades and fueled community excitement for a significant rebound. Despite ongoing competitive pressures and recent price adjustments, investors are focusing on improved profitability and potential for a sustained upside.

S&P Global, Inc. engages in the provision of transparent and independent ratings, benchmarks, analytics, and data to the capital and commodity markets worldwide. It operates through the following segments: Market Intelligence, Ratings, Commodity Insights, Mobility, Indices, and Engineering Solutions. The Market Intelligence segment provides multi-asset-class data and analytics integrated with purpose-built workflow solutions. The Ratings segment is involved in credit ratings, research, and analytics, offering investors and other market participants information, ratings, and benchmarks. The Commodity Insights segment focuses on information and benchmark prices for the commodity and energy markets. The Mobility segment offers solutions serving the full automotive value chain including vehicle manufacturers, automotive suppliers, mobility service providers, retailers, consumers, and finance and insurance companies. The Engineering Solutions segment engages in advanced knowledge discovery technologies, research tools, and software-based engineering decision engines to advance innovation, maximize productivity, improve quality, and reduce risk. The company was founded by James H. McGraw and John A. Hill in 1917 and is headquartered in New York, NY.

S&P Global Inc

S&P Global is trending following a disappointing earnings report and weaker-than-expected guidance, which triggered a sharp market repricing. The community is sharply divided between those seeing a buying opportunity in an oversold "blue-chip" and those concerned about increasing competition from advanced AI models in the financial data sector.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending after pre-announcing preliminary revenue significantly above prior guidance, signaling accelerating demand from hyperscale customers and AI networking. The community is highly bullish, viewing this strong beat as validation for its critical role in the ongoing AI infrastructure build-out.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.5% - Should You Sell?

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.5% - Here's What Happened...

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 7.4% Higher - Still a Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.4% - Here's Why...

<ul class="summary-bullets"><li>On Stocktwits, retail sentiment around IOVA stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. In the three months through the end of September,</li><li>Iovance reported total product revenue of $68 million, including about $58 million from Amtagvi sales in the U.S.</li><li>In November, the company said that it expects full year 2025 revenue of $250 million to $300 million. &nbsp;</li></ul>Shares of Iovance Biotherapeutics Inc. (IOVA) garnered retail interest on Monday, as shares climbed up 8% amid anticipation from investors for positive announcements, and takeover hopes. &nbsp;On Stocktwits, retail sentiment around IOVA stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.Iovance is a commercial stage immuno-oncology company. It is seeking to deliver tumor-infiltrating lymphocyte (TIL) therapies for patients with cancer. TIL therapy is a personalized, one-time immunotherapy that extracts a patient's own, naturally occurring T-cells from their tumor, expands them to billions in a lab, and infuses them back to fight advanced cancers.<h2 class="st-heading-2">What Do Stocktwits Users Have To Say?</h2>A Stocktwits user highlighted that the company hasn’t made announcements in the recent weeks. “They've had their head down working at the grindstone. Its time for several updates!” they wrote.<stembedurl>https://www.stocktwits.com/BioCrazy1/message/642913966</stembedurl>Another highlighted takeover opportunities.<stembedurl>https://www.stocktwits.com/beachsidefreddy/message/642912870</stembedurl>Another user opined that IOVA management must have a chat with Merck in light of reports that the pharma giant is no longer in talks to acquire the cancer drug developer Revolution Medicines.<stembedurl>https://www.stocktwits.com/TopCharts/message/642896481</stembedurl><h2 class="st-heading-2">Iovance Pipeline</h2>In the three months through the end of September, Iovance reported total product revenue of $68 million, including about $58 million from Amtagvi sales in the U.S. Amtagvi is FDA-approved for the treatment of metastatic melanoma.In November, the company said that it expects full year 2025 revenue of $250 million to $300 million. 2025 marks the first full calendar year of Amtagvi sales. Analysts on average expect the company to report total revenue of $259.45 million.<a href="https://stocktwits.com/symbol/IOVA">IOVA stock</a> has fallen 54% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/whats-driving-the-uptick-in-evtv-stock-today/cmy7yYCR4hh">What’s Driving The 38% Uptick In EVTV Stock Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Iovance Biotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IOVA Shares Jump 8% — What’s Retail Expecting?

Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.

Equity

Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.


Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.4% - What's Next?

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.4% - Here's What Happened...

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1% - Here's What Happened

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1% - Should You Sell...

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 8.7% - Still a Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 8.7% - Here's Why...

Iovance Biotherapeutics, Inc. $IOVA Position Increased by Squarepoint Ops LLC

Squarepoint Ops LLC grew its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 115.2% in the 2nd quarter, according to the company in its most recent Form 13F filing...

Mirador Capital Partners LP Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA

Mirador Capital Partners LP purchased a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 3rd quarter, according to its most recent 13F filing with the...

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.7% - Should You Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.7% - What's Next...

Voss Capital LP Acquires New Shares in Iovance Biotherapeutics, Inc. $IOVA

Voss Capital LP acquired a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities...

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$2.60
Prev Close	$2.53
Open	$2.52
Dividend Yield	0.00%
50-Day Moving Average	$2.50
Beta	1.62
Avg. Volume	12.83M
PE Ratio	-2.16

52-Week High	$6.09
52-Week Low	$1.64
Market Capitalization	$1.03B
EPS (Annual)	-$1.28
Price to Book	1.43
Revenue Per Employee	$195,787.59
Enterprise Value/EBITDA	N/A

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IOVA News

IOVAIovance Biotherapeutics Inc